Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

DT120 ODT (lysergide tartrate), Definium Therapeutics' proprietary LSD formulation, is advancing through multiple Phase 3 programs for major depressive disorder (MDD) and generalized anxiety disorder (GAD), with specific enrollment milestones and topline readout timing mentioned for 2026. For MDD, the Emerge Phase 3 study is fully enrolled with 149 patients randomized to DT120 ODT 100 mcg versus placebo, with topline data expected in late 2Q 2026. For MDD, the Ascend Phase 3 study has initial sites activated and aims for first patient dosing in early 2Q 2026. For GAD, the Voyage Phase 3 study is about 80% enrolled with no sample size increase needed and topline expected in early 3Q 2026, while the Panorama Phase 3 study is on track with topline expected in 2H 2026. The company also reports full-year 2025 financial results, including $411.6 million in cash, cash equivalents, and investments as of December 31, 2025, and says it expects to fund operations into 2028. Separately, Definium's DT402 (R(-)-MDMA) program for autism spectrum disorder (ASD) is transitioning into Phase 2a after a Phase 1 single-ascending dose study, with initial Phase 2a data anticipated in 2026.